To test this hypothesis, we investigated whether PR-619, a pan-DUB inhibitor, altered expression of profibrotic markers and TGF-β1-Smad signaling molecules in a mouse model of renal fibrosis and TGF-β1-stimulated renal cells. The gene discussed is TGFB1; the disease is renal fibrosis.